These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. Engebretsen KV; Lunde IG; Strand ME; Waehre A; Sjaastad I; Marstein HS; Skrbic B; Dahl CP; Askevold ET; Christensen G; Bjørnstad JL; Tønnessen T FEBS J; 2013 May; 280(10):2382-98. PubMed ID: 23480731 [TBL] [Abstract][Full Text] [Related]
4. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Herum KM; Lunde IG; Skrbic B; Louch WE; Hasic A; Boye S; Unger A; Brorson SH; Sjaastad I; Tønnessen T; Linke WA; Gomez MF; Christensen G Cardiovasc Res; 2015 May; 106(2):217-26. PubMed ID: 25587045 [TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642 [TBL] [Abstract][Full Text] [Related]
6. Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin. Herum KM; Romaine A; Wang A; Melleby AO; Strand ME; Pacheco J; Braathen B; Dunér P; Tønnessen T; Lunde IG; Sjaastad I; Brakebusch C; McCulloch AD; Gomez MF; Carlson CR; Christensen G J Am Heart Assoc; 2020 Feb; 9(3):e013518. PubMed ID: 32000579 [TBL] [Abstract][Full Text] [Related]
7. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Dahl CP; Husberg C; Gullestad L; Waehre A; Damås JK; Vinge LE; Finsen AV; Ueland T; Florholmen G; Aakhus S; Halvorsen B; Aukrust P; Oie E; Yndestad A; Christensen G Circ Heart Fail; 2009 Nov; 2(6):624-32. PubMed ID: 19919988 [TBL] [Abstract][Full Text] [Related]
8. Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload. Li G; Xie J; Chen J; Li R; Wu H; Zhang X; Chen Q; Gu R; Xu B Cardiovasc Pathol; 2017; 28():74-79. PubMed ID: 28395201 [TBL] [Abstract][Full Text] [Related]
9. Alpha-actinin interactions with syndecan-4 are integral to fibroblast-matrix adhesion and regulate cytoskeletal architecture. Okina E; Grossi A; Gopal S; Multhaupt HA; Couchman JR Int J Biochem Cell Biol; 2012 Dec; 44(12):2161-74. PubMed ID: 22940199 [TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of syndecan-4 upregulation by TNF-α in the endothelium-like EAhy926 cells. Okuyama E; Suzuki A; Murata M; Ando Y; Kato I; Takagi Y; Takagi A; Murate T; Saito H; Kojima T J Biochem; 2013 Jul; 154(1):41-50. PubMed ID: 23576453 [TBL] [Abstract][Full Text] [Related]
11. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Grall F; Gu X; Tan L; Cho JY; Inan MS; Pettit AR; Thamrongsak U; Choy BK; Manning C; Akbarali Y; Zerbini L; Rudders S; Goldring SR; Gravallese EM; Oettgen P; Goldring MB; Libermann TA Arthritis Rheum; 2003 May; 48(5):1249-60. PubMed ID: 12746898 [TBL] [Abstract][Full Text] [Related]